Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All subjects~* Age 18-40.~* Read, signed and dated informed consent.~* Women of childbearing potential must use an acceptable method of contraception~Group 1: Healthy subjects~* No history of atopic dermatitis as documented in the patient file~* No active atopic dermatitis~* No other atopic disorders such as asthma or allergic rhinitis.~* Prick test without clinical significance~* IgE within normal range~Group 2: Subjects with history of atopic dermatitis~Group 3: Subjects with mild active atopic dermatitis~- SCORAD 1 - 15.~Group 4: Subjects with mild allergic rhinitis~* At least one active allergic rhinitis phase during last year.~Exclusion Criteria:~* Known or suspected history of smallpox vaccination or typical vaccinia scar.~* Positive test result in MVA specific ELISA at screening.~* Positive result in HIV or HCV antibody test at screening.~* Surface antigen of Hepatitis B Virus (HBsAg) positive at screening.~* Pregnant or breast-feeding women.~* Positive pregnancy test at screening and/or within 24 hours prior to vaccination.~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the institutional upper limit of normal.~* Positive urine glucose by dipstick or urine analysis.~* Inadequate renal function defined as a serum creatinine above the institutional upper limit of normal; urine protein \>30 mg/dl or trace proteinuria (by urine analysis or dipstick); and a calculated creatinine clearance \<80 ml/min.~* Electrocardiogram (ECG) with clinical significance.~* Hemoglobin \<11 g/dl; White blood cells less than 2,500 and more than 11,000/mm3; Platelets less than 140,000/mm3.~* Uncontrolled serious infection i.e. not responding to antimicrobial therapy.~* History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject.~* History of or active autoimmune disease.~* Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment.~* History of malignancy.~* History or clinical manifestation of clinically significant mental illness or haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or gastrointestinal disorders.~* Any condition which might interfere with study objectives.~* History of immunodeficiency.~* History of myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, or other heart condition under the care of a doctor.~* Three or more of the following risk factors: High blood pressure, high blood cholesterol, diabetes mellitus or high blood sugar, a first degree relative who had a heart condition before the age of 50, smoking cigarettes.~* History of chronic alcohol abuse and/or intravenous drug abuse.~* History of allergic reactions likely to be exacerbated by any component of the vaccine.~* History of anaphylaxis or severe allergic reaction.~* Acute disease (illness with or without a fever) at the time of enrollment.~* Any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion.~* Chronic administration of immuno-suppressant or immune-modifying drugs.~* Post organ transplant subjects whether or not receiving chronic immunosuppressive therapy.~* Administration or planned administration of immunoglobulins and/or any blood -- Use of any investigational or non-registered drug.~* Blood donation 8 weeks in advance or during study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- GP 1: healthy, no AD (Type: EXPERIMENTAL): Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
- GP2: prev. allerg. rhinitis (Type: EXPERIMENTAL): Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
- GP3: history of AD (Type: EXPERIMENTAL): Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
- GP4: active AD (Type: EXPERIMENTAL): Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete